Report Highlights
The global demand for immunoassay testing was nearly $15.6 billion in 2011 and $16.3 billion in 2012. This market is expected to grow to $20.5 billion by 2017, at a compound annual growth rate (CAGR) of 4.7% from 2012 to 2017.
Report Includes
- An overview of the global market for growth of immunoassay technology in clinical, food safety, and environmental areas.
- Analysis of global market trends, with data provided for 2011 and 2012, and projections, with five-year compound annual growth rates (CAGRs), through 2017.
- Discussion of government regulations and technology patents and the roles they play in development.
- Analysis of new markets.
- Comprehensive company profiles of major players.
Report Scope
The scope of this study encompasses an investigation of the markets for the following immunoassay testing categories: enzyme, fluorescence, radio-immunoassay (RIA), cardiac analysis, infectious diseases, and tumor diagnosis. BCC analyzes each immunoassay examination type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues including the latest trends are discussed. BCC analyzes the industry on a worldwide basis, both from an application and demand point of view in the major regions of the world.
Analyst Credentials
Carlet Auguste is president and CEO of Efficiency Engineering Inc., a consulting firm that provides technology engineering services to corporations and nonprofit organizations. He consults regularly with government and private industry companies from a variety of fields of engineering to help create technology innovations for the private sector as well as government customers needing technology solutions for national defense. He previously worked for a U.S. government agency in the area of intelligence and security.
Report Highlights
-
As the human genome-sequencing project nears completion and other organisms' genomes are sequenced, the number of known proteins increases. Many proteins are currently being used and will be used as diagnostic tools in immunoassays. Immunoassays are used in a variety of applications: medical diagnostics, infectious disease testing, drug testing, home use, hormones, veterinary diagnostic, cancer, tissue typing, research, food testing, environmental testing, industrial chemicals, plant disease diagnostics, and biotechnology products testing. Enzyme-linked immunosorbent, chemiluminescent, fluorescent, radio-labeled, and immunoprecipitation are some of the old and new immunoassay technologies being used. New immunoassay technologies are also being developed. Since the number of known proteins and the potential number of immunoassays are increasing, it is interesting to analyze the current and developing immunoassay technologies and markets.
-
This report is an analytical tool whose primary purpose is to show increased growth in the current and emerging clinical, food safety, and environmental immunoassay fields. The report discusses specific, patented technology, the role of government regulation and patents that affect the development and growth of the various immunoassay markets.
Related Reports
Antibody Drugs: Technologies and Global Markets
The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
Labeling and Linkage Agents for Immunoassays and Gene Probes
The market for immunoagents, probes and molecular diagnostics was $29.6 billion in 2010. This market is projected to be $33.5 billion in 2011 and will increase up to $60.3 billion by 2016 at a compound annual growth rate (CAGR) of 12.5%.
Cell-based Assays: Technologies and Global Markets
Cell biology is currently the biggest revenue contributor to the life-science tools industry, accounting for approximately 30% of total sales. It is expected to grow to a $15 billion market by 2015, increasing at a compound annual growth rate (CAGR) of 12.3% from its 2010 value of $8.5 billion.
Life Science Tools and Reagents: Global Markets
The life science tools market has shown steady growth over the last couple of years despite the economic downturn. This market is currently valued at more than $42 billion and is projected to increase at compound annual growth rate (CAGR) of 13.6% to reach approximately $81 billion in 2016.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More